ATE392210T1 - Methoden zur behandlung von festen tumoren und metastasen mit gentherapie - Google Patents
Methoden zur behandlung von festen tumoren und metastasen mit gentherapieInfo
- Publication number
- ATE392210T1 ATE392210T1 AT00968760T AT00968760T ATE392210T1 AT E392210 T1 ATE392210 T1 AT E392210T1 AT 00968760 T AT00968760 T AT 00968760T AT 00968760 T AT00968760 T AT 00968760T AT E392210 T1 ATE392210 T1 AT E392210T1
- Authority
- AT
- Austria
- Prior art keywords
- gene therapy
- metastasis
- methods
- solid tumors
- treating solid
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 238000009166 antihormone therapy Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15806899P | 1999-10-07 | 1999-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE392210T1 true ATE392210T1 (de) | 2008-05-15 |
Family
ID=22566564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00968760T ATE392210T1 (de) | 1999-10-07 | 2000-10-07 | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1223952B1 (de) |
| JP (2) | JP5557974B2 (de) |
| AT (1) | ATE392210T1 (de) |
| AU (1) | AU7862600A (de) |
| CA (1) | CA2386374A1 (de) |
| DE (1) | DE60038624T2 (de) |
| WO (1) | WO2001024684A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
| JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| AU2003247094A1 (en) * | 2002-07-19 | 2004-02-09 | Ludwig Institute For Cancer Research | Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| JP2007511507A (ja) | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
| JP4560629B2 (ja) * | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| EP3268362B1 (de) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituierte pyridine und verwendungen davon |
| IL309273A (en) | 2015-10-21 | 2024-02-01 | Teclison Ltd | Preparations and methods for curing cancer with immune support |
| EP3205356A1 (de) * | 2016-02-10 | 2017-08-16 | Onkoloski Institut Ljubljana | Plasmidexpressionsvektor zur codierung von humanem interleukin 12 unter transkriptionskontrolle von p21-promotor und ohne antibiotikaresistenz für krebsgentherapie und andere verwendungen davon |
| WO2018183635A1 (en) | 2017-03-31 | 2018-10-04 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| CN112955130A (zh) | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| IL298219A (en) | 2020-05-15 | 2023-01-01 | Algen Biotechnologies Inc | Certain chemical compositions and methods of use thereof |
| WO2021256427A1 (ja) * | 2020-06-15 | 2021-12-23 | 株式会社Kortuc | 抗がん療法の増感剤 |
| KR102570785B1 (ko) * | 2021-05-06 | 2023-08-24 | 연세대학교 산학협력단 | 화학방사선요법에 대한 정보 제공 방법 및 이를 적용한 디바이스 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| CA2113990A1 (en) * | 1991-07-26 | 1993-02-18 | Frederick L. Moolten | Cancer therapy utilizing malignant cells |
| US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| JP2001515493A (ja) * | 1997-03-14 | 2001-09-18 | セレクティブ ジェネティックス,インコーポレイテッド | 改変された親和性を有するアデノウイルスベクター |
| AU2656299A (en) * | 1998-02-03 | 1999-08-16 | Baylor College Of Medicine | Synergism between thymidine kinase gene therapy and topoisomerase i and topoisomerase ii inhibitors |
-
2000
- 2000-10-07 DE DE60038624T patent/DE60038624T2/de not_active Expired - Lifetime
- 2000-10-07 EP EP00968760A patent/EP1223952B1/de not_active Expired - Lifetime
- 2000-10-07 AT AT00968760T patent/ATE392210T1/de not_active IP Right Cessation
- 2000-10-07 JP JP2001527689A patent/JP5557974B2/ja not_active Expired - Fee Related
- 2000-10-07 WO PCT/US2000/027547 patent/WO2001024684A2/en not_active Ceased
- 2000-10-07 AU AU78626/00A patent/AU7862600A/en not_active Abandoned
- 2000-10-07 CA CA002386374A patent/CA2386374A1/en not_active Abandoned
-
2011
- 2011-10-03 JP JP2011219632A patent/JP2012001566A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001024684A2 (en) | 2001-04-12 |
| EP1223952B1 (de) | 2008-04-16 |
| JP5557974B2 (ja) | 2014-07-23 |
| CA2386374A1 (en) | 2001-04-12 |
| DE60038624D1 (de) | 2008-05-29 |
| EP1223952A2 (de) | 2002-07-24 |
| WO2001024684A3 (en) | 2001-10-25 |
| AU7862600A (en) | 2001-05-10 |
| DE60038624T2 (de) | 2009-06-10 |
| EP1223952A4 (de) | 2004-12-08 |
| JP2003528813A (ja) | 2003-09-30 |
| JP2012001566A (ja) | 2012-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60038624D1 (de) | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie | |
| MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
| ATE425749T1 (de) | Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs | |
| TW200728465A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| DK1165108T3 (da) | Anvendelse af et ekstrakt af Serenoa repens til fremstilling af et lægemiddel til behandling af prostatacancer | |
| ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| WO2002066044A3 (en) | Method for dendritic cells based immunotherapy of tumors using combination therapy | |
| NO20000752L (no) | Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser | |
| IL178042A0 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
| EA200501937A1 (ru) | Способ лечения злокачественных опухолей | |
| WO1999051263A3 (en) | Methods and modified cells for the treatment of cancer | |
| NO20002412L (no) | FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler | |
| DE60044350D1 (de) | Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs | |
| ATE296663T1 (de) | Vorrichtung zur behandlung von tumoren | |
| DE60212415D1 (de) | Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren | |
| ATE252896T1 (de) | Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs | |
| UA88294C2 (ru) | ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК | |
| ATE383154T1 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| AU2013204147B2 (en) | Treatment of TNFalpha related disorders | |
| ATE527282T1 (de) | Tumor assoziierte antigene | |
| ATE291620T1 (de) | Mammakarzinom-assoziiertes gen | |
| MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. | |
| ATE435284T1 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| CY1116323T1 (el) | ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
| WO2001028573A3 (en) | Monocyte conditioned medium for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |